Short Interest in Genfit S.A. (OTCMKTS:GNFTF) Declines By 72.8%

Genfit S.A. (OTCMKTS:GNFTF) was the recipient of a large drop in short interest in August. As of August 14th, there was short interest totaling 763 shares, a drop of 72.8% from the July 30th total of 2,805 shares. Based on an average daily volume of 8 shares, the days-to-cover ratio is currently 95.4 days.

Genfit Price Performance

GNFTF stock remained flat at $15.75 during midday trading on Thursday. Genfit has a 52 week low of $4.14 and a 52 week high of $16.50. The company’s fifty day moving average price is $13.54 and its two-hundred day moving average price is $11.19.

Genfit Company Profile

Genfit is a clinical‐stage biopharmaceutical company headquartered in Lille, France, specializing in the development of innovative therapies and diagnostics for liver and metabolic diseases. The company’s research and development efforts are primarily focused on non‐alcoholic steatohepatitis (NASH), a progressive liver disorder with significant unmet medical needs. Genfit’s lead therapeutic candidate, elafibranor, is designed to target key pathways involved in inflammation, fibrosis and lipid metabolism, positioning it as a potential treatment for patients with NASH and associated metabolic complications.

In addition to its therapeutic pipeline, Genfit has established a diagnostic arm centered on NIS4®, a proprietary blood‐based test that leverages transcriptomic biomarkers to enable earlier and more accurate detection of liver fibrosis in patients at risk for NASH.